Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.
Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, van der Woude CJ, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Daretti LM, Marzioni M, Yimam KK, Perin N, Floreani A, Beretta-Piccoli BT, Rogers JK; International Primary Sclerosing Cholangitis Study Group (IPSCSG); Levy C.
Lynch KD, et al.
Clin Gastroenterol Hepatol. 2020 Jan;18(1):179-187.e6. doi: 10.1016/j.cgh.2019.05.013. Epub 2019 May 14.
Clin Gastroenterol Hepatol. 2020.
PMID: 31100458
Free PMC article.